Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL885701 | 0.92 | RIPK1 (0.52) | RIPK1KDRHDAC1HDAC8HDAC6 | |
| SCHEMBL2060255 | 0.89 | RIPK1 (0.47) | RIPK1KDRMAPK14MCHR1ULK1 | |
| SCHEMBL2060127 | 0.89 | KDR (0.54) | RIPK1KDRHDAC1HDAC8HDAC6 | |
| SCHEMBL885586 | 0.88 | KIT (0.50) | RIPK1KDRHDAC1HDAC8HDAC6 | |
| SCHEMBL885848 | 0.86 | RIPK1 (0.47) | RIPK1KDRHDAC1HDAC8HDAC6 | |
| SCHEMBL885792 | 0.85 | HDAC1 (0.43) | RIPK1KDRHDAC1MAPK14MCHR1 | |
| SCHEMBL885592 | 0.85 | KDR (0.48) | RIPK1KDRHDAC1HDAC8HDAC6 | |
| SCHEMBL885866 | 0.82 | RIPK1 (0.51) | RIPK1KDRKITBRAFMCHR1 | |
| SCHEMBL885846 | 0.80 | KDR (0.41) | RIPK1KDRHDAC1HDAC8HDAC6 | |
| SCHEMBL2060043 | 0.78 | RIPK1 (0.52) | RIPK1KITBRAFMCHR1ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | claimed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | claimed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | claimed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | claimed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | claimed |
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| WO-2008060907-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | IGF1R, FGFR1, FLT1 | RIPK1 850/4885KDR 5/4885HDAC1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.